Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 374 participants.

Also called NCT02068443

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 374 participants (enrolled count) (from the registry)
Sponsor
  • Takeda Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02068443
  • WHO UTN U1111-1151-6515
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02068443. Randomized; quadruple masking; primary purpose treatment. Start 2014-02 (registry gives no type); primary completion 2015-02 (actual). Results posted on 2016-06-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Alogliptin
Intervention (Drug)
Metformin hydrochloride
Intervention (Drug)
Metformin hydrochloride Placebo
Lead sponsor
Takeda (class: industry)

Record details

Record id
cardio:ct-nct02068443
Content hash
99162ebd3b365757b1f642ab0c267035120bfd2aab77e0a23e65b9e21f7bdaa9